Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research
News Apr 23, 2009
Roche NimbleGen and Sigma-Aldrich have started a collaboration to further chromatin immunoprecipitation on microarray (ChIP-chip) research by aligning their two complementary technologies, Roche NimbleGen’s ChIP-chip high-density microarrays and GenomePlex™ by Sigma-Aldrich.
Together, the platforms enable researchers to effectively study the entire genome for epigenetic interactions between DNA and DNA-binding proteins to determine regions of the genome that are transcriptionally active or repressed and the mechanisms that regulate these processes.
Understanding the fundamental epigenomic and genomic regulatory pathways underlying normal cell growth and tissue differentiation, as well as changes in regulatory control associated with disease, is crucial for the development of drugs that target these pathways.
To facilitate the ChIP-chip workflow, Roche NimbleGen and Sigma-Aldrich will publish protocols for ChIP-chip research and provide technical support to researchers integrating the two technologies, as well as co-market their complementary products.
ChIP-chip combines chromatin immunoprecipitation (ChIP) with microarrays to understand DNA-protein interactions. The ChIP step deploys a specific antibody against a regulatory protein of interest, which results in the enrichment of DNA fragments bound to the target protein. Usually these enriched DNA fractions are at very low concentrations and need to be further amplified for detection.
The technologies from Sigma-Aldrich and Roche NimbleGen facilitate ChIP-chip research by addressing two critical bottlenecks in the workflow: efficient amplification of targeted sections of DNA and high-resolution microarray detection.
For researchers, GenomePlex is the preferred method for amplifying targeted small (less than 200bp) DNA fragments in an efficient and unbiased manner. The amplified genome can then be analyzed on Roche NimbleGen’s high density (up to 2.1 million probes per array), long oligonucleotide, ChIP-chip arrays to examine the interactions between DNA and proteins such as transcription factors, histones and polymerases.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE